2024: A Breakthrough Year for CAR T-Cell Brain Cancer Therapy

Dr. Carl June, the “Father of CAR T-Cell Therapy”, believes 2024 will be marked as a breakthrough year for brain cancer treatment, specifically for patients with glioblastoma, a highly aggressive form of brain cancer.

As Dr. June recently told Forbes, glioblastoma is a death sentence, with the average glioblastoma patient having just 15-18 months survival time, and a survival rate of just 5% after five years.

However, recent studies conducted by several research groups, including a group lead Dr. June, involving CAR T-Cell infusions have shown promise for glioblastoma patients.

“We published six patients just about a month and a half ago in an ongoing trial with a dual CAR given into the brain.

“And all six patients had really quite remarkable imaging changes very rapidly. I think about five years down the line, we’re going to have FDA-approved CARs for glioblastoma,” said Dr. June.

As the “Father of CAR T-Cell Therapy”, Dr. June treated the first patients with CAR T-cell therapy back in 2010. And, as reported in Forbes, the results were “astonishing.”

By 2017, the FDA approved the first T Cell therapy drug, with six approved for market today.

Dr. Wee Kiat Tan, co-CEO of CytoMed Therapeutics (NASDAQ: GDTC) said, “While 2024 has indeed represented a year of breakthrough for cancer therapies and we are very heartened by the glioblastoma treatment showing promise, we believe that next year, 2025 could offer even grander advancement in the cancer therapeutics field.

“With the anticipation of our clinical trials slated to begin later this year, unlike conventional CAR-T therapy, which is limited to hematological disorders, our “off-the-shelf” gamma delta T cells can target both hematological disorders and solid tumors as well.

“Hence, 2025 can be a true breakthrough for cancer therapies as well as for CytoMed as well.”

Read the full article HERE

Or watch CytoMed Therapeutics’ (NASDAQ:GDTC) latest investor presentation, HERE